JNJ 61186372

Drug Profile

JNJ 61186372

Alternative Names: Bispecific EGFR-cMet antibody

Latest Information Update: 07 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Immunomodulators; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 01 May 2016 Janssen Research & Development initiates a phase I trial for Non-small cell lung cancer (Metastatic disease, Inoperable/Unresectable) in South Korea (IV) (NCT02609776)
  • 31 Dec 2015 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Inoperable/Unresectable) in South Korea (IV)
  • 24 Nov 2015 Preclinical trials in Non-small cell lung cancer in USA (Parenteral) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top